Metphio Tablet 15/850 mg
Metformin Hydrochloride 850mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
MFDS item code 201904569 · Approved 2019.07.05
This product's status changed to Approval withdrawn on 2025.03.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improves blood glucose control in patients with type 2 diabetes
This medication is used in combination with pioglitazone and metformin to help control blood sugar in patients with type 2 diabetes. It is primarily administered alongside dietary and exercise therapy to effectively improve blood sugar levels. This helps streamline blood sugar management for patients and alleviates symptoms of diabetes.
For the treatment of patients with type 2 diabetes mellitus, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum dose of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the dose of metformin or pioglitazone currently being taken. Start with 1 tablet of this medicine once daily, assess the adequacy of the treatment response, and adjust the dose gradually. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start with their existing doses of pioglitazone and metformin. No studies have evaluated the safety and efficacy of switching to this medicine from other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may alter glycemic control; use caution and ensure appropriate monitoring. 3. Patients with renal impairment: All dose adjustments should be based on careful assessment of renal function. In general, older adults, debilitated patients, and malnourished patients should not be titrated up to the maximum dose of this medicine. After this medicine is administered to a patient, or when the dose is increased, the patient must be carefully monitored for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals, which can reduce gastrointestinal adverse reactions caused by metformin. Allow sufficient time to assess the adequacy of the treatment response. Ideally, the response to treatment should be evaluated using glycated hemoglobin (HbA1C), which is a better indicator of long-term glycemic control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, if glycemic control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) is recommended to assess changes in HbA1C.
This medication can cause severe lactic acidosis and hypoglycemia, so it should be used with extreme caution. Lactic acidosis, although rare, is a life-threatening condition that occurs more frequently in patients with reduced kidney function or problems with the heart or lungs. If sudden symptoms such as difficulty breathing, muscle pain, weakness, or abdominal pain occur while taking this medication, notify your doctor immediately. Patients with impaired liver function or excessive alcohol consumption should avoid using this medication. It should not be used in patients with severe heart failure, and if symptoms of heart failure appear, immediate medical attention is required. Patients with active bladder cancer or a history of bladder cancer should carefully weigh the risks and benefits before using this medication. Patients with moderate or severe renal impairment, severe heart failure, or who are pregnant or breastfeeding should not take this medication. This medication should not be administered to patients with certain genetic diseases. Patients with irregular meals or intense exercise routines, or those taking other medications should be cautious as they may be at risk of lactic acidosis and hypoglycemia. Regular blood tests and renal function tests should be performed while taking this medication, and vitamin B12 deficiency should also be checked. When undergoing surgery or tests involving contrast agents, this medication should be temporarily discontinued under medical supervision. Side effects such as weight gain, edema, headaches, and indigestion may occur, so consult a doctor if these symptoms are severe. It is advised not to use this medication during pregnancy or while breastfeeding. Elderly patients may have a higher risk of declining kidney function, so dose adjustment and careful monitoring are essential. In cases of overdose, visit a hospital immediately for appropriate treatment, which may include hemodialysis.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. Keep the storage temperature between 1 to 30 degrees Celsius.
White to off-white rectangular film-coated tablets
30 tablets / PTP [10 tablets/PTP X 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Metformin Hydrochloride 850mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
Pioglitazone Hydrochloride 16.53mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 850mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationMetformin Hydrochloride 850mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Dalim Biotech Co., Ltd.
CombinationPioglitazone Hydrochloride 16.53mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Kyungdong Pharmaceutical Co., Ltd.
Metformin Hydrochloride · Pioglitazone Hydrochloride
Prescription medication · Combination
Nexpam Korea Co., Ltd.
CombinationPioglitazone Hydrochloride 16.53mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 850mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Ilhwa Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.